ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 Cells

International Journal of Gynecological Pathology

Volumn 31, Issue 6, 2012, Pages 532-537

  Chen, Aiping ^a   Qian, Dongmeng ^a   Wang, Bin ^a   Hu, Ming ^a   Lu, Jinrong ^a   Qi, Yani ^a   Liu, David X ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; ATF5; Bcl 2; Ovarian carcinoma; SKOV 3 cell

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ACTIVATING TRANSCRIPTION FACTOR 5; B CELL LEUKEMIA LYMPHOMA 2; CELL PROTEIN; PROTEIN BCL 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; REGULATOR GENE; REGULATORY MECHANISM; TUMOR DIFFERENTIATION;

ACTIVATING TRANSCRIPTION FACTORS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84867396538     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31824df26b     Document Type: Article

References (11)

1. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:457-515.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009;136: 823-37.
3. Hai TW, Liu F, Coukos WJ, et al. Transcription factor ATF cDNA clones: An extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 1989;3:2083-90.
4. Dluzen D, Li G, Tacelosky D, et al. Bcl-2 is a downstream target of ATF5 that mediates ATF5 pro-survival function in a cell type-dependent manner. J Biol Chem 2011;286: 7705-13.
5. Monaco SE, Angelastro JM, SzabolcsM, et al. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007;120:1883-90.
6. Pascual M, Gomez-Lechon MJ, Castell JV, et al. ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: Implications in hepatic stress responses. Drug Metab Dispos 2008;36:1063-72.
7. Sheng Z, Li L, Zhu LJ, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 2010;16:671-7.
8. Mittal AK, Hegde GV, Aoun P, et al. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Int J Mol Med 2007;20:461-9.
9. Angelastrol JM, Canoll PD, Kuo J, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 2006;25:907-16.
10. Sheng Z, Li L, Zhu LJ, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 2010;16:671-7.
11. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.